for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ブリストル・マイヤーズ・スクイブ・カンパニー

BMY.N

現在値

75.57USD

変化

1.11(+1.49%)

出来高

1,764,144

本日のレンジ

74.58

 - 

75.71

52週レンジ

53.22

 - 

80.57

∙ 約20分前の相場を表示しています。

適時開示

Bristol Myers Squibb And 2Seventy Bio announce topline results from Karmma-3 Trial showing Abecma

Aug 10 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL MYERS SQUIBB AND 2SEVENTY BIO ANNOUNCE TOPLINE RESULTS FROM KARMMA-3 TRIAL SHOWING ABECMA (IDECABTAGENE VICLEUCEL) SIGNIFICANTLY IMPROVES PROGRESSION-FREE SURVIVAL VERSUS STANDARD REGIMENS IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA.BRISTOL-MYERS SQUIBB CO - RESULTS OF A PRE-SPECIFIED INTERIM ANALYSIS CONDUCTED THROUGH AN INDEPENDENT REVIEW COMMITTEE SHOWED THAT KARMMA-3 MET ITS PRIMARY ENDPOINT.BRISTOL-MYERS SQUIBB - TREATMENT WITH ABECMA SHOWED AN IMPROVEMENT IN KEY SECONDARY ENDPOINT OF OVERALL RESPONSE RATE COMPARED TO STANDARD REGIMENS.BRISTOL-MYERS SQUIBB CO - FOLLOW-UP FOR OVERALL SURVIVAL, A KEY SECONDARY ENDPOINT, REMAINS ONGOING.BRISTOL-MYERS - SAFETY RESULTS IN TRIAL WERE CONSISTENT WITH PREDICTABLE SAFETY PROFILE OF ABECMA PREVIOUSLY DEMONSTRATED IN PIVOTAL KARMMA TRIAL.

Bristol-Myers Squibb Co Sees 2022 GAAP EPS Of $2.71-$3.01; Reaffirms 2022 Non-GAAP EPS Guidance

July 27 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL-MYERS SQUIBB CO - QTRLY GAAP EARNINGS PER SHARE $0.66; QTRLY NON-GAAP EARNINGS PER SHARE $1.93.BRISTOL-MYERS SQUIBB CO - QTRLY REVENUE $11.9 BILLION, UP 2% YOY; OR 5% WHEN ADJUSTED FOR FOREIGN EXCHANGE.BRISTOL-MYERS SQUIBB CO - QTRLY WORLDWIDE ELIQUIS REVENUE $3,235 MILLION, UP 16%.BRISTOL-MYERS SQUIBB CO - QTRLY WORLDWIDE OPDIVO REVENUE $2,063 MILLION, UP 8%.BRISTOL-MYERS SQUIBB CO SEES 2022 U.S. GAAP REVENUE OF $46.0 BILLION.BRISTOL-MYERS SQUIBB CO SEES 2022 GAAP EPS OF $2.71-$3.01; REAFFIRMS 2022 NON-GAAP EPS GUIDANCE.

U.S. FDA Approves Bristol Myers Squibb'S Car T Cell Therapy Breyanzi For Relapsed Large B-Cell Lymphoma

June 24 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::U.S. FDA APPROVES BRISTOL MYERS SQUIBB’S CAR T CELL THERAPY BREYANZI® FOR RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA AFTER ONE PRIOR THERAPY.BMY - SINGLE INFUSION OF BREYANZI SIGNIFICANTLY OUTPERFORMED NEARLY 30-YEAR STANDARD OF CARE.

Bristol-Myers Squibb To Present Lung Cancer Data At ASCO Annual Meeting

June 6 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::THREE-YEAR DATA FROM PHASE 3 CHECKMATE -9LA TRIAL DEMONSTRATE LONG-TERM, DURABLE SURVIVAL OUTCOMES OF OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) WITH TWO CYCLES OF CHEMOTHERAPY FOR PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER.BRISTOL-MYERS SQUIBB CO - LATE-BREAKING DATA TO BE PRESENTED DURING 2022 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING.BRISTOL-MYERS SQUIBB - DUAL IMMUNOTHERAPY-BASED COMBINATION CONTINUED TO SHOW SUSTAINED IMPROVEMENT IN OVERALL SURVIVAL, TRIAL'S PRIMARY ENDPOINT.BRISTOL-MYERS SQUIBB - NO NEW SAFETY SIGNALS OBSERVED WITH OPDIVO PLUS YERVOY WITH 2 CYCLES OF CHEMOTHERAPY WITH EXTENDED FOLLOW-UP IN CHECKMATE -9LA.BRISTOL-MYERS SQUIBB - LONG-TERM, DURABLE CLINICAL BENEFIT OF OPDIVO,YERVOY WITH 2 CYCLES OF CHEMOTHERAPY OBSERVED AT 3 YRS ACROSS PATIENT POPULATIONS.

Bristol-Myers Squibb Presents Lung Cancer Treatment Data At Annual Oncology Conference

June 6 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::LANDMARK FIVE-YEAR DATA FROM PHASE 3 CHECKMATE -227 TRIAL DEMONSTRATE LONG-TERM, DURABLE SURVIVAL OUTCOMES WITH OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER.BRISTOL-MYERS - OPDIVO PLUS YERVOY NEARLY DOUBLED OVERALL SURVIVAL RATE AT 5 YRS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH PD-L1 EXPRESSION ≥1%.BRISTOL-MYERS SQUIBB CO - SAFETY PROFILE FOR DUAL IMMUNOTHERAPY COMBINATION REMAINED CONSISTENT WITH PREVIOUSLY REPORTED DATA FROM THIS TRIAL.

Bristol Myers Squibb Withdraws Supplemental Biologics License Application (SBLA) For Reblozyl (LUSPATERCEPT-AAMT) For Non-Transfusion Dependent (NTD) Beta Thalassemia

June 3 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL MYERS SQUIBB WITHDRAWS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR REBLOZYL® (LUSPATERCEPT-AAMT) FOR NON-TRANSFUSION DEPENDENT (NTD) BETA THALASSEMIA.BRISTOL-MYERS SQUIBB CO - COULD NOT APPROPRIATELY ADDRESS U.S. FDA'S QUESTIONS ABOUT BENEFIT-RISK PROFILE OF REBLOZYL FROM PHASE 2 BEYOND TRIAL.BRISTOL-MYERS SQUIBB - CONTINUING TO EVALUATE REBLOZYL IN A BROAD CLINICAL DEVELOPMENT PROGRAM.

Bristol Myers Squibb To Acquire HBM Portfolio Company Turning Point Therapeutics For USD 4.1 Bln In Cash

June 3 (Reuters) - HBM HEALTHCARE INVESTMENTS AG <HBMN.S>::BRISTOL MYERS SQUIBB TO ACQUIRE HBM PORTFOLIO COMPANY TURNING POINT THERAPEUTICS FOR USD 4.1 BILLION IN CASH.TODAY ANNOUNCES THAT ITS PORTFOLIO COMPANY TURNING POINT THERAPEUTICS (NASDAQ: TPTX) WILL BE ACQUIRED BY BRISTOL MYERS SQUIBB (NYSE: BMY) IN AN ALL-CASH TRANSACTION THAT VALUES COMPANY AT USD 4.1 BILLION.ACQUISITION PRICE OF USD 76.-- PER SHARE REPRESENTS A PREMIUM OF APPROXIMATELY 122 PERCENT TO CLOSING SHARE PRICE ON 2 JUNE 2022.TRANSACTION IS EXPECTED TO CLOSE DURING Q3 2022.

Bristol Myers Squibb To Acquire Turning Point Therapeutics For $4.1 Bln

June 3 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL MYERS SQUIBB TO ACQUIRE TURNING POINT THERAPEUTICS, A LEADING PRECISION ONCOLOGY COMPANY.BRISTOL-MYERS SQUIBB CO - DEAL FOR $76.00 PER SHARE.BRISTOL-MYERS SQUIBB CO - DEAL EXPECTED TO BE ACCRETIVE TO NON-GAAP EARNINGS PER SHARE BEGINNING IN 2025.BRISTOL-MYERS SQUIBB CO- EXPECTS TO FINANCE ACQUISITION WITH CASH ON HAND.BRISTOL-MYERS SQUIBB CO - ALL-CASH TRANSACTION FOR A TOTAL CONSIDERATION OF $4.1 BILLION IN EQUITY VALUE.BRISTOL-MYERS SQUIBB - DEAL EXPECTED TO BE UP TO $0.08 PER SHARE DILUTIVE TO NON-GAAP EPS IN 2022 PRIOR TO ANY IMPACT FROM AN ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT CHARGE.BRISTOL-MYERS SQUIBB - TURNING POINT THERAPEUTICS' BOARD UNANIMOUSLY RECOMMENDS THAT SHAREHOLDERS TENDER THEIR SHARES IN TENDER OFFER.BRISTOL-MYERS SQUIBB - ACCOUNTING TREATMENT AS A BUSINESS COMBINATION OR ASSET ACQUISITION WILL BE DETERMINED UPON EXPECTED CLOSE OF DEAL IN Q3.

Immatics, Bristol Myers Squibb Expand Alliance To Develop Gamma Delta Allogeneic Cell Therapy Programs

June 2 (Reuters) - Immatics NV <4A3.F>::IMMATICS AND BRISTOL MYERS SQUIBB EXPAND STRATEGIC ALLIANCE TO DEVELOP GAMMA DELTA ALLOGENEIC CELL THERAPY PROGRAMS.IMMATICS - IMMATICS TO RECEIVE UPFRONT PAYMENT OF $60 MILLION AND ADDITIONAL MILESTONE PAYMENTS OF UP TO $700 MILLION PER PROGRAM PLUS TIERED ROYALTY PAYMENTS.IMMATICS - BRISTOL MYERS SQUIBB, CO WILL DEVELOP 2 PROGRAMS OWNED BY BRISTOL MYERS, BOTH COS HAVE OPTION TO DEVELOP UP TO 4 ADDITIONAL PROGRAMS EACH.IMMATICS - CO WILL BE RESPONSIBLE FOR PRECLINICAL DEVELOPMENT OF INITIAL TWO BRISTOL MYERS SQUIBB-OWNED PROGRAMS.IMMATICS - CO WILL RECEIVE ADDITIONAL PAYMENT FOR CERTAIN ACTIVITIES THAT IMMATICS COULD PERFORM AT BRISTOL MYERS SQUIBB'S REQUEST.IMMATICS - BRISTOL MYERS SQUIBB AND IMMATICS WILL EXPAND THEIR 2019 COLLABORATION AGREEMENT FOCUSED ON AUTOLOGOUS T CELL RECEPTOR-BASED THERAPY.IMMATICS - AS PART OF EXPANSION, IMMATICS WILL RECEIVE AN UPFRONT PAYMENT OF $20 MILLION AND BE ELIGIBLE FOR MILESTONE PAYMENTS AND ROYALTIES.

U.S. Food And Drug Administration Approves Two Opdivo® (Nivolumab)-Based Regimens As First-Line Treatments

May 27 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::U.S. FOOD AND DRUG ADMINISTRATION APPROVES TWO OPDIVO® (NIVOLUMAB)-BASED REGIMENS AS FIRST-LINE TREATMENTS FOR UNRESECTABLE ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA.BRISTOL-MYERS SQUIBB CO - OPDIVO-BASED TREATMENTS ARE NOW APPROVED FOR FIVE INDICATIONS IN UPPER GASTROESOPHAGEAL CANCERS.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up